In a bold move that’s turning heads in the tech and healthcare sectors, Anthropic has launched an internal AI drug discovery program. At a San Francisco event, Eric Kauderer-Abrams, Anthropic’s life sciences head, announced the company’s mission to focus on treatments for “neglected” diseases—those often overlooked by traditional biopharmaceutical companies.
Kauderer-Abrams emphasised the importance of getting hands-on: “We believe in the power of tight feedback loops, and there’s no substitute for having our own experiences alongside you all in the trenches trying to develop drugs.” This approach aims to create AI tools that truly resonate with the needs of drugmakers.
While Anthropic hasn’t detailed what happens if they discover promising drug candidates, their status as a public benefit company allows them to prioritise patient benefit over commercial interests. They’re keeping their cards close to their chest but promise to share more as their work progresses.
Anthropic joins a growing list of tech giants betting on healthcare. Companies like Alphabet, Apple, and Amazon have all ventured into this space, with varying degrees of success. Anthropic aims to stand out by focusing on neglected diseases and collaborating with drugmakers through their new Claude Science product.
This initiative marks a significant step in the convergence of AI and healthcare, promising exciting developments for the future. Keep an eye on this space as Anthropic and other tech titans continue to innovate and transform the industry.
Image: Unsplash
Want to hear more? Join Mal & Matt on the Property AI Report Podcast each week!
Access from your preferred podcast provider by clicking here
Made with TRUST_AI - see the Charter: https://www.modelprop.co.uk/trust-ai